N-Acetyl Semax Amidate

Last Updated: August 2026

N-Acetyl Semax Amidate (Ac-MEHFPGP-NH₂) is a structural analog of Semax carrying two terminal modifications — N-terminal acetylation and C-terminal amidation. Capping a peptide's ends this way is a standard, well-understood way to slow the aminopeptidases and carboxypeptidases that degrade it, so the analog is expected to resist enzymatic breakdown better than unmodified Semax. What that means for its half-life or potency in a living body has not been measured in any published pharmacokinetic study, and the "longer-acting" or "more potent" figures repeated by vendors are community estimates rather than established data. It is a distinct compound from native Semax — not an alias — though the two are closely mechanistically related. N-Acetyl Semax Amidate is not approved by any major regulator and is sold as a research-use-only compound by third-party laboratories.

What is N-Acetyl Semax Amidate and how does the modified mechanism work?

N-Acetyl Semax Amidate is Semax (Met-Glu-His-Phe-Pro-Gly-Pro) with two structural modifications: N-terminal acetylation (Ac-) and C-terminal amidation (-NH₂), which together confer resistance to aminopeptidase and carboxypeptidase degradation and extend half-life relative to native Semax. The pharmacological effects are similar to Semax — BDNF upregulation, neuroprotection, cognitive performance effects — but the longer half-life supports less-frequent dosing in research protocols. Evidence level: No published studies of the variant itself; the rodent cognition / BDNF data and the Russian clinical record are for parent Semax; no Western Phase 2/3 RCT.

What does the research show for N-Acetyl Semax Amidate?

The BDNF, cognitive-performance and ischemic-neuroprotection findings usually cited for this compound come from studies of parent Semax, not the N-acetyl amidate analog. As of August 2026 a PubMed search for "N-acetyl semax amidate" returns no results, and the peer-reviewed literature on acetylated Semax is limited to peptide-chemistry work on its proteolytic stability1 source and its metal-ion coordination — not efficacy or pharmacokinetic trials of the commercial variant. That the analog is "longer-acting" than Semax is a reasonable chemical expectation, but it has not been shown in a published head-to-head study. See the Semax profile for the underlying human and preclinical evidence. Russian research has explored the modified analog as a potential improvement on the Semax pharmacokinetic profile. Formal Phase 2/3 clinical evidence at Western standards is not available. Evidence level: Preclinical; Russian research; FDA-grade Phase 2/3 not conducted.

How does N-Acetyl Semax Amidate compare to Semax?

N-Acetyl Semax Amidate is the longer-acting structural analog of Semax, sharing the parent compound's mechanism with extended duration per dose.

N-Acetyl Semax Amidate sits in Peptigrity's cognitive and neuroprotection peptides category.

What are the documented side effects of N-Acetyl Semax Amidate?

Side effects in available preclinical data and community-reported research use are mild — generally similar to Semax with occasional mild stimulation effects. Long-term safety in humans at sustained research-use dosing is not characterized at Western RCT standards. Evidence level: Preclinical safety; human long-term unestablished.

What is the regulatory status of N-Acetyl Semax Amidate?

N-Acetyl Semax Amidate is not approved for any medical indication anywhere in the world as of August 2026. Unlike native Semax — which the FDA removed from Category 2 of the 503A bulk-substances lists in April 2026 because the original nominations were withdrawn by the nominators, not as a safety clearance1 source — the N-acetyl amidate analog has never been part of the FDA's 503A nominations, categories, or PCAC schedules, and as a research-only compound it sits outside that compounding framework entirely (as of August 2026). Regulatory context in FDA peptide regulation 2025–2026 timeline.

Why does N-Acetyl Semax Amidate vendor verification matter — and the Semax mislabeling risk?

The structural similarity between N-Acetyl Semax Amidate (Ac-MEHFPGP-NH₂) and native Semax (MEHFPGP) creates a substantial mislabeling risk — the two modifications shift the molecular weight only slightly — acetylation adds about 42 Da and C-terminal amidation removes roughly 1 Da, a net change of about +41 Da from Semax's parent mass of ~813.9 Da1 source — which is exactly why mass spectrometry is the tool that tells the analog apart from parent Semax and from mislabeled plain Semax, which mass spectrometry can distinguish, but basic HPLC may not. Independent third-party HPLC with mass spectrometry identity confirmation is essential. Buyers paying for "N-Acetyl Semax Amidate" should verify they are not receiving native Semax (which is typically cheaper). Guidance in how-to-test-peptides hub. Compare vendors against the independent N-Acetyl Semax Amidate lab tests on file.

How does Peptigrity verify N-Acetyl Semax Amidate vendors?

Peptigrity collects independent third-party Certificates of Analysis for N-Acetyl Semax Amidate from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Mass spec is particularly important to verify the acetyl and amide modifications. Methodology in how we calculate trust scores.

Frequently Asked Questions

Is N-Acetyl Semax Amidate the same as Semax?

No. N-Acetyl Semax Amidate is a structural analog of Semax with N-terminal acetylation and C-terminal amidation modifications. They are different molecules with related effects; the modified analog has longer half-life. They are not aliases or interchangeable products.

Is N-Acetyl Semax Amidate legal to purchase?

N-Acetyl Semax Amidate is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.

Will N-Acetyl Semax Amidate be FDA-approved?

No active FDA approval pathway exists for N-Acetyl Semax Amidate as of August 2026. Unlike native Semax (which is in PCAC review for July 2026), the modified analog was not specifically included in the April 2026 Category 2 removals.

How can I verify an N-Acetyl Semax Amidate vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation to verify the acetyl and amide modifications. This is essential because basic HPLC may not distinguish N-Acetyl Semax Amidate from native Semax. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend an N-Acetyl Semax Amidate dose?

No. N-Acetyl Semax Amidate is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies. Anyone considering use should consult a licensed physician.

Why use N-Acetyl Semax Amidate over Semax?

The primary practical difference is half-life — the modified analog requires less-frequent dosing for sustained effects. Russian clinical practice has favored native Semax for established approved indications; the modified analog is more typically used in research and community contexts where dosing convenience matters.

This section is for educational and informational purposes only and does not constitute medical advice. N-Acetyl Semax Amidate is not approved by the FDA or equivalent regulators for human use; it is sold as a research compound. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.